Androgenetic alopecia (AGA), a prevalent form of hair loss, has limited approved therapies, primarily topical minoxidil and oral finasteride, whose efficacy is constrained by poor transdermal absorption and systemic side effects, respectively. Microneedling (MN) is a minimally invasive procedure that overcomes these constraints by bypassing the stratum corneum to enhance topical drug delivery and by inducing controlled microtrauma to promote hair follicle regeneration through wound‐healing pathways. This review comprehensively examines the mechanisms, clinical effectiveness, and safety of MN in AGA treatment, with emphasis on its synergistic role in combination therapies involving platelet‐rich plasma (PRP), finasteride, dutasteride, and minoxidil. Preliminary results from small‐scale studies suggest potential benefits; however, most available evidence is of low to moderate quality due to small sample sizes, short follow‐up periods, and heterogeneous protocols. Larger well‐designed randomized controlled trials with long‐term follow‐up are needed to confirm its clinical role. By bridging the gap between topical therapies and surgical intervention, MN represents a potential patient‐friendly platform for AGA management pending further high‐quality validation. This review further distinguishes classical MN, which relies on physical stimulation without drug loading, from drug‐loaded microneedle systems, which serve as integrated platforms for both drug loading and delivery, clarifying their distinct mechanisms, evidence levels, and clinical applicability.
He et al. (Thu,) studied this question.